Use of oxazolidinone derivatives for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy

摘要

Use of an oxazolidinone selected from: (S)-N- [ [3- [3-fluoro-4- [4- (hydroxyacetyl)-1-piperazinyl]-phenyl]-2-oxo-5oxazolidinyl] methyl] acetamide, (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5oxazolidinyl] methyl] acetamide, [4(S)-cis]-(-)-N-[[3-[3-fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2oxo-6-oxazolidinyl3methyUacetamide N- ( (5S)-3- (3-fluoro-4- (4- (2-fluoroethyl)-3-oxopiperazin-1-yl) phenyl)-2oxooxazolidin-5-ylmethyl) acetamide, (S)-N- [ [3- [5- (3-pyridyl) thiophen-2-yl]-2-oxo-5-oxazolidinyl] methyl] acetamide and (S)-N- [ [3- [5- (4-pyridyl) pyrid-2-yl]-2-oxo-5-ogazolidinyl] methyl] acetamide and pharmaceutically acceptable salts thereof for the manufacture of a medicament for use in treating psoriasis, arthritis or for reducing damage to hematopoietic cells and intestinal cells in a person being treated with one or more anti-cancer chemotherapeutic agents, where the human to be treated does not have a gram positive bacterial infection.